Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 8, 2014

Primary Completion Date

October 27, 2017

Study Completion Date

February 14, 2021

Conditions
Brain Tumor, RecurrentGlioblastomaAnaplastic AstrocytomaAnaplastic OligodendrogliomaMixed Glioma
Interventions
PROCEDURE

Cytoreductive surgery

Standard of care/routine cytoreductive glioma resection surgery. Arm B only.

DRUG

Perifosine

Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.

DRUG

Temsirolimus

Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.

Trial Locations (2)

10032

Columbia University Irving Medical Center, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

AEterna Zentaris

INDUSTRY

lead

Andrew B Lassman, MD

OTHER

NCT02238496 - Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | Biotech Hunter | Biotech Hunter